---
title: "Waldencast: Regulatory Overhang Cleared, Brand Growth Prospects Support Buy Rating and Unchanged $2 Price Target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284787453.md"
description: "Analyst Susan Anderson of Canaccord Genuity has maintained a Buy rating on Waldencast with an unchanged price target of $2.00, citing the resolution of regulatory uncertainty and the strength of the brand portfolio. With the SEC investigation concluded, she anticipates reduced legal expenses, allowing focus on growth initiatives. Key brands like Milk Makeup and Obagi show significant global growth potential, supporting her outlook. Additionally, Alliance Global Partners also holds a Buy rating with a $2.50 price target."
datetime: "2026-04-30T13:55:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284787453.md)
  - [en](https://longbridge.com/en/news/284787453.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284787453.md)
---

# Waldencast: Regulatory Overhang Cleared, Brand Growth Prospects Support Buy Rating and Unchanged $2 Price Target

Analyst Susan Anderson of Canaccord Genuity maintained a Buy rating on Waldencast, retaining the price target of $2.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Susan Anderson has given his Buy rating due to a combination of factors tied to the resolution of regulatory uncertainty and the strength of Waldencast’s brand portfolio. With the SEC investigation concluded and no enforcement action planned, she expects legal and professional expenses to subside, freeing cash and management attention to be redirected toward growth initiatives and strategic options, including potential brand or company-level transactions.

Anderson also highlights that the underlying businesses, particularly Milk Makeup and Obagi, retain meaningful global growth potential despite recent volatility in results. She points to Obagi’s continued expansion in injectables and aesthetic products and Milk’s international distribution gains as evidence of durable brand equity, supporting her unchanged $2 price target and reinforcing the risk‑reward profile at current valuation levels.

In another report released yesterday, Alliance Global Partners also maintained a Buy rating on the stock with a $2.50 price target.

### Related Stocks

- [WALD.US](https://longbridge.com/en/quote/WALD.US.md)
- [WALDW.US](https://longbridge.com/en/quote/WALDW.US.md)

## Related News & Research

- [Obagi and Next Health Partner to Launch “The Skin Recharge Station” Pop-Up Experience | WALD Stock News](https://longbridge.com/en/news/286414830.md)
- [Obagi Medical Shares New Data on Recent Innovations at Music City Symposium for Cosmetic Advances & Laser Education (SCALE) Meeting | WALD Stock News](https://longbridge.com/en/news/286563656.md)
- [Waldencast announces conclusion of SEC investigation | WALD Stock News](https://longbridge.com/en/news/284456778.md)
- [This Analyst Just Sent Mobileye Stock Down. Here's Why.](https://longbridge.com/en/news/286817003.md)
- [11:32 ETThe Future of Brand Growth: Kantar Unites Global Visionaries to Honor the Year's Most Valuable Brands](https://longbridge.com/en/news/286940048.md)